CANAGLIFLOZIN, A SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT-2) BLOCKER, NORMALIZES BLOOD GLUCOSE WITHOUT AFFECTING SYSTEMIC BLOOD PRESSURE, OXIDATIVE STRESS, INTRARENAL ANGIOTENSINOGEN GENE EXPRESSION AND KIDNEY INJURY IN TYPE 1 DIABETIC MICE

被引：0
|
作者：
Chan, John S. D. [1 ]
Chenier, Isabelle [1 ]
Ghosh, Anindya [1 ]
Wu, Chin-Han [1 ]
Lo, Chao-Sheng [1 ]
Zhao, Shuiling [1 ]
Chiasson, Jean-Louis [1 ]
Filep, Janos G. [2 ]
Ingelfinger, Julie R. [3 ]
Zhang, Shao-Ling [1 ]
机构：
[1] CHUM, Res Ctr, Montreal, PQ, Canada
[2] Hop Maison Neuve Rosemont, Res Ctr, Montreal, PQ H1T 2M4, Canada
[3] Massachusetts Gen Hosp, Pediat Nephrol Unit, Boston, MA 02114 USA
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2016年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
SP374
引用
收藏
页码：214 / 214
页数：1
相关论文
共 50 条
  • [31] Angiotensin II up-regulates sodium-glucose co-transporter 2 expression and SGLT2 inhibitor attenuates Ang II-induced hypertensive renal injury in mice
    Miyata, Kana N.
    Lo, Chao-Sheng
    Zhao, Shuiling
    Liao, Min-Chun
    Pang, Yuchao
    Chang, Shiao-Ying
    Peng, Junzheng
    Kretzler, Matthias
    Filep, Janos G.
    Ingelfinger, Julie R.
    Zhang, Shao-Ling
    Chan, John S. D.
    CLINICAL SCIENCE, 2021, 135 (07) : 943 - 961
  • [32] Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on major cardiovascular events in Type 2 diabetic patients: a meta-analysis of randomized controlled trials
    Bardi, Luca
    Paolillo, Stefania
    Bruzzese, Dario
    Esposito, Cristina
    Ambrosio, Antonio
    Prastaro, Maria
    Chirico, Alfonsina
    Colella, Angela
    Perrone-Filardi, Pasquale
    Gargiulo, Paola
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (0G)
  • [33] Peri-procedural management of sodium-glucose co-transporter 2 (SGLT-2) inhibitors and prevention of euglycaemic diabetic ketoacidosis (EUDKA): Early experience from a tertiary specialist cardiothoracic centre
    Di Palma, R.
    Vanderpuye, A.
    DIABETIC MEDICINE, 2020, 37 : 134 - 135
  • [34] Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on major cardiovascular events in Type 2 diabetic patients: a meta-analysis of randomized controlled trials
    Bardi, Luca
    Paolillo, Stefania
    Bruzzese, Dario
    Esposito, Cristina
    Ambrosio, Antonio
    Prastaro, Maria
    Chirico, Alfonsina
    Colella, Angela
    Perrone-Filardi, Pasquale
    Gargiulo, Paola
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (SUPPL G)
  • [35] Renal effects of sodium glucose co-transporter 2 inhibitors in Japanese type 2 diabetes mellitus patients with home blood pressure monitoring
    Kobayashi, Kazuo
    Toyoda, Masao
    Kimura, Moritsugu
    Hatori, Nobuo
    Furuki, Takayuki
    Sakai, Hiroyuki
    Takihata, Masahiro
    Umezono, Tomoya
    Ito, Shun
    Suzuki, Daisuke
    Takeda, Hiroshi
    Kanamori, Akira
    Degawa, Hisakazu
    Yamamoto, Hareaki
    Machimura, Hideo
    Mokubo, Atsuko
    Chin, Keiichi
    Obana, Mitsuo
    Hishiki, Toshimasa
    Aoyama, Kouta
    Nakajima, Shinichi
    Umezawa, Shinichi
    Shimura, Hidetoshi
    Aoyama, Togo
    Sato, Kazuyoshi
    Miyakawa, Masaaki
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 2019, 41 (07) : 637 - 644
  • [36] Sodium-glucose co-transporter 1 and 2 expression in the mammary artery of patients with bypass surgery: role of the pro-inflammatory response and contribution to oxidative stress
    Park, S. H.
    Amissi, S.
    Algara-Suarez, P.
    Gong, D. S.
    Mroueh, A.
    Belcastro, E.
    Matsushita, K.
    Bruckert, C.
    Chaker, A. B.
    Jesel, L.
    Ohlmann, P.
    Morel, O.
    Mazzucotelli, J. P.
    Schini-Kerth, V. B.
    EUROPEAN HEART JOURNAL, 2021, 42 : 3440 - 3440
  • [37] A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats
    Yui Takeshige
    Yoshihide Fujisawa
    Asadur Rahman
    Wararat Kittikulsuth
    Daisuke Nakano
    Hirohito Mori
    Tsutomu Masaki
    Koji Ohmori
    Masakazu Kohno
    Hiroaki Ogata
    Akira Nishiyama
    Hypertension Research, 2016, 39 : 415 - 422
  • [38] A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats
    Takeshige, Yui
    Fujisawa, Yoshihide
    Rahman, Asadur
    Kittikulsuth, Wararat
    Nakano, Daisuke
    Mori, Hirohito
    Masaki, Tsutomu
    Ohmori, Koji
    Kohno, Masakazu
    Ogata, Hiroaki
    Nishiyama, Akira
    HYPERTENSION RESEARCH, 2016, 39 (06) : 415 - 422
  • [39] Decreased expression of Glucagon-like peptide-1 receptor and Sodium-glucose co-transporter 2 in patients with proliferative diabetic retinopathy
    Chen, Hui
    Zhang, Xiongze
    Liao, Nanying
    Ji, Yuying
    Mi, Lan
    Gan, Yuhong
    Su, Yongyue
    Wen, Feng
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [40] Sodium-glucose co-transporter 2 inhibitors (SGLT2i); as a preventive factor of kidney failure in patients with type 2 diabetes; a meta-analysis of randomized controlled trials
    Jahangiri, Dorsa
    Padhi, Udit Narayan
    Verma, Henu Kumar
    Lakkakula, Bhaskar V. K. S.
    Valizadeh, Rohollah
    Nasri, Hamid
    JOURNAL OF RENAL INJURY PREVENTION, 2021, 10 (04): : 1 - 8
12345